ArticleOral health & preventive dentistry2026
A Retrospective Cohort Study of Medication-Related Osteonecrosis of the Jaw (MRONJ) Prevention.
Article in Oral health & preventive dentistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMedication-related osteonecrosis of the jaw (MRONJ) is a serious complication that can arise in patients receiving antiresorptive or antiangiogenic therapy. Despite known predisposing factors, effective prophylaxis is currently little used. We therefore sought to assess the standardised prevention protocols that are used in our institution for reducing MRONJs among at-risk patients and to quantify the consistency of the effects. METHODS AND MATERIALS: This retrospective cohort study analysed 422 dental extraction records from 126 patients who had received antiresorptive or antiangiogenic therapy. The extractions were classified into four risk levels based on medication class, cumulative treatment duration, comorbidity burden and immunosuppression status. The effect of the prevention protocol was estimated using Mantel-Haenszel stratified analysis, with the risk level as the stratifying variable, and the homogeneity of the effect was assessed using the Breslow-Day test.
resultsMRONJ developed in 94.1% of extractions performed without prevention protocols and in only 6.7% with prophylactic protocols; Mantel-Haenszel stratified analysis - adjusting for the baseline risk level - produced a common OR of 0.0044 (95% CI: 0.0010-0.0195, p 0.0001). Stratum-specific estimates were consistent across all three risk levels, and the Breslow-Day test confirmed the homogeneity of the effect.
conclusionsMantel-Haenszel stratified analysis confirmed consistent protective effects of the applied prevention protocols, with different proportionality, across every risk level. This study proposes the first stratified quantification of prevention protocol effectiveness across a validated composite risk scoring system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.